#familialhypercholesterolemia

[fromsciencetopharma]

AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme #Astrazeneca #PCSK9 “The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for #dyslipidaemia and #familialhypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is abnormal amount of lipids like low-density lipoprotein (LDL cholesterol) or bad cholesterol present in the blood. On the other hand, familial hypercholesterolemia is a common genetic condition that leads to high cholesterol. According to AstraZeneca, PCSK9 is a protein that controls the LDL cholesterol levels in the blood. Heightened activity of the protein is related to high LDL cholesterol, said the company. The acquired PCSK9 inhibitors by AstraZeneca are small molecules which directly bind to a novel part of the protein. In preclinical models, the inhibitors have shown to prevent the protein’s activity and had resulted in lower LDL cholesterol. Presently, there are no oral inhibitors of the protein that are either available to patients or in clinical development, said the pharma major. https://www.instagram.com/p/CFX4am1j8v3/?igshid=fqf75cs002dj

[mariebenz]

Monoclonal Antibody Evinacumab is a Major Benefit to Patients with Homozygous Familial Hypercholesterolemia

MedicalResearch.com Interview with:

Professor F. J. Raal Professor F. J. Raal, FRCP, FCP(SA), Cert Endo, MMED, PhD Director, Carbohydrate & Lipid Metabolism Research Unit Professor & Head, Division of Endocrinology & Metabolism, Faculty of Health Sciences, University of the Witwatersrand MedicalResearch.com: What is the background for this study? How does Evinacumab differ from the three drugs used in triple therapy for this severe form of hypercholesterolemia? Response:      Despite available lipid lowering therapies, the vast majority of patients with homozygous familial hypercholesterolemia are unable to achieve desirable LDL-cholesterol levels and remain at high risk for premature atherosclerotic cardiovascular disease. Unlike statins and PCSK9-inhibitors which act mainly by upregulating LDL receptor activity on the cell surface, evinacumab, a monoclonal antibody inhibitor of ANGPTL3, acts independent of the LDL receptor. MedicalResearch.com: What are the main findings? Response:     In this phase III study in 65 subjects with homozygous familial hypercholesterolemia  randomized to evinacumab or placebo, evinacumab reduced LDL-cholesterol by 49% compared to placebo, an absolute reduction in LDL-cholesterol of 132 mg/dL (3.4 mmol/L)  which is remarkable. The drug was equally effective in those homozygous familial hypercholesterolemia patients with minimal or no residual LDL receptor function. MedicalResearch.com: What should readers take away from your report? Response: Evinacumab can substantially reduce LDL-cholesterol levels in homozygous familial hypercholesterolemia patients regardless of LDL receptor function and is an effective treatment option for these high risk patients who are unable to reach LDL-cholesterol target despite multiple lipid-lowering therapies with or without apheresis.  MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: The addition of evinacumab is of major benefit to patients with homozygous familial hypercholesterolemia as it halves their LDL-cholesterol levels and with ongoing treatment, provided there are no long-term safety issues, this is likely to markedly reduce their risk for premature cardiovascular disease and improve survival. MedicalResearch.com: Is there anything else you would like to add? Response: With the addition of evinacumab to the other lipid lowering therapies available (statins, ezetimibe plus PCSK9 inhibitors) we will change the natural history of homozygous familial hypercholesterolemia from one that is often lethal in childhood to a manageable and treatable lipid disorder. My disclosures: I have received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from Sanofi, Regeneron, Amgen and The Medicines Company.  Citation: Raal F. Evinacumab in patients with homozygous familial hypercholesterolemia. Presented on: March 30, 2020. ACC 2020. The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

[mrpeaceandliberty]

#Repost @mrpeaceandliberty (@get_repost) ・・・ "Despite the fact that LDL-C is routinely referred to as the ‘bad cholesterol’, we have shown that high LDL-C levels appear to be unrelated to the risk of CVD, both in Familial hypercholesterolemia individuals and in the general population and that the benefit from the use of cholesterol-lowering drugs is questionable. . . Therefore, a systematic search for other CVD risk factors is an important topic for future research." . . LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature Uffe Ravnskov Journal Expert Review of Clinical Pharmacology Volume 11, 2018 . . #ldlc #ldlcholesterol #badcholesterol #badcholesterolpl #cardiovasculardisease #cardiovasculardiseaseprevention #cardiovasculardiseases #benifitsofnutrition #heartdiseasecauses #cholesterollowering #ldl #badcholesterol #goodcholesterol #familialhypercholesterolemia #liesmydoctortoldme @antonioworldwide @american_heart @departmentofveteransservices @deptvetaffairs @amermedicalassn @department_of_health @kendberry.md @malpracticeone #lieskill #deadlylies Please #repost liberally! https://www.instagram.com/p/B2-c_JPgTw-/?igshid=n4a987hsdvug

[hdlhub]

Celebrate FH Awareness Day Today: 9/24/14

Familial hypercholesterolemia (FH) is a genetic condition that causes lifelong elevations of LDL cholesterol (the “bad cholesterol”). FH runs in families and is estimated to affect as many as 1 in 200 individuals. People with FH usually feel and look healthy, and many are not even aware that they have it. However, FH is a very serious condition because the high levels of cholesterol in the blood often lead to significantly increased risks for premature heart disease, stroke, or even death.

Fortunately, FH is highly treatable, especially when diagnosed early. Although diet and exercise alone are not usually enough to manage FH, there are many medications and treatments that can delay or prevent the development of heart disease.

You and your family members may be at risk for FH if you have:

A personal history of very high LDL-C (greater than 190 mg/dL) and total cholesterol levels (greater than 300 mg/dL)

A family history of high cholesterol, early heart disease, and/or heart attacks

If you are concerned about a possible diagnosis or family history of FH, talk to your doctor. Health Diagnostic Laboratory, Inc. has educational resources available for both patients and providers through our Familial Hypercholesterolemia (FH) Program. 

-HDL Inc. Clinical Health Consultant Allison Goodwin, MS, Certified Genetic Counselor

For more information on nutrition for exercise and other lifestyle tips, contact Client Services at 877-443-5227 to set up an appointment with a Health Diagnostic Laboratory, Inc. Clinical Health Consultant today! 

[mrpeaceandliberty]

"Despite the fact that LDL-C is routinely referred to as the ‘bad cholesterol’, we have shown that high LDL-C levels appear to be unrelated to the risk of CVD, both in Familial hypercholesterolemia individuals and in the general population and that the benefit from the use of cholesterol-lowering drugs is questionable. . . Therefore, a systematic search for other CVD risk factors is an important topic for future research." . . LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature Uffe Ravnskov Journal Expert Review of Clinical Pharmacology Volume 11, 2018 . . #ldlc #ldlcholesterol #badcholesterol #badcholesterolpl #cardiovasculardisease #cardiovasculardiseaseprevention #cardiovasculardiseases #benifitsofnutrition #heartdiseasecauses #cholesterollowering #ldl #badcholesterol #goodcholesterol #familialhypercholesterolemia #liesmydoctortoldme @american_heart @departmentofveteransservices @deptvetaffairs @amermedicalassn @department_of_health @kendberry.md @malpracticeone #lieskill #deadlylies https://www.instagram.com/p/BzqSnYeAtrx/?igshid=1mhhsqn73hhv1

[dietplusminus]

Yes, now you can manage excess cholesterol by diet and minimal exercise at home =============================== 🏋️💯💛💚💙💜🤎🤞💯🎁🎊 Not all the cholesterols are bad, excess amount either in the diet or formation by the liver creates problems. It's not too late. Let's fight together... Reach us @ 9582292288 #cholesterol #cholesterolfree #highcholesterol #nocholesterol #lowercholesterol #reducecholesterol #cholesteroltips #goodcholesterol #zerocholesterol #cholesterolcontrol #badcholesterol #lowcholesteroldiet #cholesteroldiet #anticholesterol #cholesterolawareness #loweryourcholesterol #cholesterolmyth #healthycholesterol #lowercholesterolnaturally #cholesterollevels #noanimalcholesterol #highcholesterolproblems #cholesterolsupport #hypercholesterolemia #ldlcholesterol #familialhypercholesterolemia #lesscholesterol #highcholesterollife #cholesterolproblems (at Delhi, India) https://www.instagram.com/p/CZ8Z5QEBt_s/?utm_medium=tumblr